drugsTreatmentPhase 3

DZD8586

aka Birelentinib

DZD8586 is an experimental small-molecule drug from Dizal Pharmaceuticals in phase 3 trials for chronic lymphocytic leukaemia and diffuse large B-cell lymphoma, with its target not yet stated publicly.

DZD8586 is a small-molecule drug developed by Dizal Pharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07139873 (A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)), in chronic lymphocytic leukaemia and diffuse large B-cell lymphoma. The largest, NCT07139873, plans to enrol 250 participants with primary completion expected 2029-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How targeted therapy works, step by step · animated schematic, not to scale; chosen from the modality "small molecule"

Targeted Therapy →

Modality

small molecule

Mechanism

Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

DZD8586

intervention: DZD8586

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.